Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 167 participants.

Also called NCT03329261

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 167 participants (enrolled count) (from the registry)
Sponsor
Laboratoires Teriak (from the registry)
Registry
  • NCT NCT03329261
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Tunisia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03329261. Randomized; no masking; primary purpose treatment. Start 2017-12-07 (actual); primary completion 2019-03-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
Acronym
IDASCOP 1
Condition
Diabetes Mellitus, Type 2
Condition
NSTEMI - Non-ST Segment Elevation MI
Condition
Coronary Angioplasty
Intervention (Drug)
Clopidogrel
Lead sponsor
Laboratoires Teriak (class: industry)

Record details

Record id
cardio:ct-nct03329261
Content hash
39d85dc951a1744f757147561149800ed45d9652055615261262b3d656e2c7de